Key Takeaways
- FY26 revenue grew 29%, balanced across segments: CRO contributed 24% and CDMO 33%, with large pharma now 49% of revenue vs 28% in FY22, reflecting a structural shift in sourcing toward India.
- CDMO pipeline is deep but lumpy: 34 commercial molecules, 11 in Phase III/pre-registration, and ~155 earlier-stage programs provide multi-year visibility, though quarterly revenue remains inherently uneven.
- Margins held within the aspirational band: Management reiterated a 28–30% steady-state EBITDA margin target, citing open-book pharma pricing as a natural guardrail, while acknowledging near-term dilution from new capacity ramp-ups.
- New modalities revenue dipped, not derailed: Contribution fell from 7% to 4% because the work is clinical-campaign-driven and episodic, not because of lost positioning; peptide and ADC capabilities are being built now.
- What to watch next quarter: Whether the 5 incremental Phase III/pre-registration additions convert to commercial traction, the pace of biotech funding recovery flowing into CRO, and any margin impact from the INR1,100–1,300 cr capex cycle now beginning.
CDMO: Commercial Scale-Up and Pipeline Depth
- Commercial base expanding: 34 commercial molecules after adding one more this quarter, with at least a couple expected to begin production and generate commercial revenue this year.
- Late-stage pipeline thickened: Phase III/pre-registration molecules rose from ~6 to 11, with 5 incremental additions, most of them small molecule and one a new modality under validation.
- Large pharma consolidation tailwind: Some Phase III additions resulted from pharma companies consolidating long-term outsourcing partners in India, a trend management expects to continue.
- Dedicated FTE model scaling: Large pharma customers are starting FTE agreements for late-stage and mid-stage development, with dedicated teams across India and Manchester sites, deepening integration and retention.
- Capacity build-out is front-loaded: The plan to expand from 700 KL to 1,150 KL sees the majority of capex fall in FY27, with 225 KL of the 450 KL addition coming online in H2 FY27; brownfield expansions take 12–15 months, greenfield 24–30 months.
- Molecule retention advantage: The integrated discovery-development-commercial model, with approval across all three departments, gives higher retention probability than competitors, though some leakage occurs from capacity gaps, diversity needs, or in-sourcing.
Krishna Kanumuri: "we're the only company really stitched all these together and we're approved by all three of these areas. And that's the strength why we believe that we can retain a majority of the molecules, but that said, some molecules definitely leak out of us... the chances of us retaining are higher than most other players at this point." [8-9]
CRO: Large Pharma Influx and Biotech Recovery
- Structural shift in discovery sourcing: Large pharma contribution to CRO is rising as every major pharma now looks to build an India footprint for discovery, up from only two or three actively doing med-chem in India three years ago.
- Biotech funding recovering: Biotech funding is up 52% YoY year-to-date, and management expects the biotech segment to pick up over the next 24 months, restoring balance to the CRO mix.
- Integrated Discovery gaining traction: The strategy is resonating particularly with biotech customers, while cross-selling opportunities with CDMO large pharma customers are emerging.
- FDA tailwind for new approach methodologies: Regulatory push toward newer approach methodologies is expected to reshape discovery workflows, favoring CROs with integrated capabilities.
- Pharma-biotech mix in transition: Pharma currently has a higher revenue share than biotech due to market dynamics; long-term the 50/50 ratio is expected to hold, but pharma may drive growth for the next couple of years.
Krishna Kanumuri: "I think large pharma is very clear that they want to build the India footprint. I think the large pharma business did not exist in India a couple of years ago. There were only two, three large pharma who were actively doing med-chem in India, I would say as close as three years back. But now every large pharma is looking at coming to India to do discovery."
New Modalities: Episodic Revenue, Capability Build Underway
- Revenue salience fell on campaign timing, not demand loss: New modalities dropped from 7% to 4% of revenue because the work is clinical pipeline, not commercial, and campaigns are episodic with waiting periods between them, not a one-off event.
- Peptide development capability coming this year: The company is adding development capability including pilot scale, with capex having started last year.
- ADC capability being added at discovery level: Work on the ADC development side is underway, with a public announcement promised when ready.
- Fast-follower philosophy governs modality bets: Management explicitly positions as a fast follower, close enough to pivot with trends but not on the bleeding edge where investment can turn dead; over 5–7 years the mix is expected to follow pharma trends (50% small molecule, 30% peptides/oligonucleotides/ADCs), but the sequence is unpredictable.
- No near-term revenue target given: Management declined to provide a ballpark revenue contribution figure for new modalities by FY30, stating the company is not far enough along to give projections.
Krishna Kanumuri: "The important part of being a CRO, in our opinion, is to be a fast follower, be close enough to be able to change the trend, but not be on the bleeding edge where you're left with the dead investment."
Margins: Guardrails, Dilution, and the Capex Cycle
- 28–30% EBITDA is the steady-state aspiration: Management committed to reaching this range in 2–3 years, citing open-book pharma pricing as a natural ceiling and floor that makes the range comfortable from a customer perspective.
- New capacity ramp-ups create near-term inefficiency: Operating leverage is being offset by inefficiency from scaling new capacity, a dynamic that will persist as the INR1,100–1,300 cr capex cycle unfolds.
- Asset turn will dip before recovering: The medium-term commitment of 1.2x to 1.4x net asset turn will see a dip due to doubling down on capex, with a 2–3 year ramp-up period typical for any capex.
- Geopolitical cost pressure is real but manageable: Middle East tensions are impacting input costs, logistics, and shipment delays; the company is approaching customers for cost revisions but recovery may not be contemporaneous.
- Capex funded through internal accruals and debt: Management declined to split the funding mix between debt and cash flow, but confirmed the plan is calibrated to the evolving business environment.
Siva Chittor: "with pharma generally there's an open-book pricing and from what we've seen, and we've seen this across the Chinese companies operating at much larger scale, the margins tend to remain between the 25% to 30%, which is what we've seen and our pricing with pharma indicates that a 28% to 30% is much more comfortable from a pharma pricing perspective."
AI and Technology: Embedded, Not Disruptive
- AI is an opportunity, not a threat to synthesis revenue: The synthesis part of drug development does not change with AI, and AI-designed moieties are more complex to make, requiring more resources per molecule; management believes R&D dollars will not drop, but more targets will be pursued with the same spend.
- Current AI impact is on lower-complexity design work: AI is attacking the lower-cost, lower-complexity parts of discovery today; the model is not yet trained on many areas, though the 5–10 year trajectory is uncertain.
- Internal AI canvas being defined: Capex is going into building AI tools and buying intangible software across assistance, automation, and analytics, with integration into large pharma systems for data transmission.
- Over 18–24 months, AI expected to embed across core workflows: Management anticipates AI and digital becoming increasingly embedded across scientific and development workflows, not as a separate revenue line but as an efficiency layer.
Krishna Kanumuri: "I think end of the day the synthesis part does not change, and the AI moieties are much more complex to make than regular synthesis. Yes, you might make fewer molecules, but the resources needed to make the molecule are more than the past... I think net-net, I think my view of AI is going to be that you probably won't drop the R&D dollars, you probably will do more with less to have more targets."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 15% to 20% CAGR on current revenue run rate of ~₹2,200 cr | Over a three-year period |
| EBITDA margin | 28% to 30% steady-state | 2–3 years |
| FY27 H2 stronger than H1 | Second half stronger due to new capacities and investments coming on stream | FY27 |
| FY27 capex | INR1,100–1,300 cr (65% CDMO, 35% CRO; 75% capacity, 25% capability/AI) | FY27 |
| Capacity expansion | 225 KL of 450 KL addition online; majority of plant capex in FY27 | H2 FY27 |
| New commercial products | At least a couple begin production and commercial revenue | FY27 |
| Net asset turn | 1.2x to 1.4x, with a dip before recovery due to capex cycle | Medium-term |
| Biotech recovery | Biotech segment expected to pick up | Next 24 months |
| AI/digital embedding | AI and digital increasingly embedded across core scientific and development workflows | 18–24 months |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue growth (FY26) | 29%, vs 16% in FY25 |
| EBITDA growth (FY26) | 56% |
| PAT growth (FY26) | 109% |
| EBITDA margin (FY26) | 30%, achieved; steady-state aspiration 28% to 30% |
| CRO segment growth (FY26) | 24% |
| CDMO segment growth (FY26) | 33% |
| Revenue growth aspiration | 15% to 20% over a three-year period |
| EBITDA margin aspiration | 28% to 30% over a three-year period |
| FY27 capex estimate | ₹1,100 cr to ₹1,300 cr, split CDMO 65%, CRO 35% |
| FY26 capex | ₹633 cr against budgeted ₹700 cr |
| Commercial molecules | 34, up from 30 in Q3 FY26 |
| Phase III/pre-registration molecules | 11, up from ~6 in Q3 FY26 |
| Revenue from top 19 pharma clients | 49% of FY26 revenue, up from 28% in FY22 |
| Top 10 customer concentration | 54% of FY26 revenue |
| Top 5 customer concentration | 37% of FY26 revenue |
| Top 1 customer concentration | 12% of FY26 revenue |
| CRO revenue mix (pharma vs biotech) | 48% vs 52% |
| H1/H2 revenue split (FY26) | 48% / 52%, vs 40%/60% in FY25 |
| Q4 share of FY26 revenue | 27%, vs 34% in Q4 FY25 |
| New technology revenue salience | 4%, down from 7% |
| Asset turn (net basis) medium-term commitment | 1.2x to 1.4x |
| Current capacity (Bidar) | ~1,150 KL |
| Capacity expansion underway | 700 KL to 1,150 KL, 225 KL expected this year, 225 KL next year |
| Capex allocation: capacity expansion | 75% of FY27 capex |
| Capex allocation: capability, AI and technology | 25% of FY27 capex |
| Biotech funding YTD growth | 52% YoY |
| April 2026 biotech funding | $10.6 bn, up over 4% YoY |